Trial intelligence / Profile preview

Dexmethylphenidate vs Methylphenidate in Children With ADHD

NCT00141050Phase 3Completed

Sponsor
Novartis
Start
May 2005
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of dexmethylphenidate in attention deficit hyperactivity disorder (ADHD) (5 arms), sponsored by Novartis. Primary endpoint: Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Score. Started May 2005; status: completed.

02

Drugs

dexmethylphenidate
03

Conditions

attention deficit hyperactivity disorder (ADHD)

Beyond the preview

Go deeper on NCT00141050.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00141050.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call